000169871 001__ 169871
000169871 005__ 20240229133658.0
000169871 0247_ $$2doi$$a10.2967/jnumed.121.261925
000169871 0247_ $$2pmid$$apmid:34272325
000169871 0247_ $$2ISSN$$a0022-3123
000169871 0247_ $$2ISSN$$a0097-9058
000169871 0247_ $$2ISSN$$a0161-5505
000169871 0247_ $$2ISSN$$a1535-5667
000169871 0247_ $$2ISSN$$a2159-662X
000169871 037__ $$aDKFZ-2021-01605
000169871 041__ $$aEnglish
000169871 082__ $$a610
000169871 1001_ $$aRöhrich, Manuel$$b0
000169871 245__ $$aFibroblast Activation Protein specific PET/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study.
000169871 260__ $$aNew York, NY$$bSoc.$$c2022
000169871 3367_ $$2DRIVER$$aarticle
000169871 3367_ $$2DataCite$$aOutput Types/Journal article
000169871 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1679920955_19456
000169871 3367_ $$2BibTeX$$aARTICLE
000169871 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169871 3367_ $$00$$2EndNote$$aJournal Article
000169871 500__ $$aF E A T U R E D A R T I C L E O F T H E M O N T HFibroblast Activation Protein–Specific PET/CT Imagingin Fibrotic Interstitial Lung Diseases and Lung Cancer:A Translational Exploratory StudyManuel Roehrich1 , Dominik Leitz2 , Frederik M. Glatting3 , Annika K. Wefers4 , Oliver Weinheimer2 , Paul Flechsig1 ,Nicolas Kahn5 , Marcus A. Mall2 , Frederik L. Giesel1 , Clemens Kratochwil1 , Peter E. Huber3 , Andreas von Deimling4 ,Claus Peter Heußel6 , Hans Ulrich Kauczor2 , Michael Kreuter*2 , and Uwe Haberkorn*1 //1 Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany; 2 Translational Lung Research CenterHeidelberg, Member of the German Center for Lung Research DZL, Heidelberg, Germany; 3 Clinical Cooperation Unit Molecular andRadiation Oncology, German Cancer Research Center, Heidelberg, Germany; 4 Department of Neuropathology, Institute of Pathology,University of Heidelberg, Heidelberg, Germany; 5 Centre for Interstitial and Rare Lung Diseases, Pneumology and Respiratory CriticalCare Medicine, Thorax Clinic, University of Heidelberg, Heidelberg, Germany; and 6 Diagnostic and Interventional Radiology withNuclear Medicine, Thoraxklinik, University of Heidelberg, Heidelberg, Germany
000169871 520__ $$aPurpose: Interstitial lung diseases (ILD) comprise over 200 parenchymal lung disorders. Among them, fibrosing ILDs, especially idiopathic pulmonary fibrosis (IPF) in particular are associated with a poor prognosis, while some others ILDs like sarcoidosis have a much better prognosis. A high proportion of ILD manifests as fibrotic ILD (fILD). Lung cancer (LC) is a frequent complication of fILD. Activated fibroblasts are crucial for fibrotic processes in fILD. The aim of this exploratory study was to evaluate the imaging properties of static and dynamic FAPI-PET/CT in various types of fILD and to confirm FAP expression of fILD lesions by FAP immunohistochemistry of human fILD biopsy samples and of lung sections of genetically engineered (Nedd4-2 -/- ) mice with an idiopathic pulmonary fibrosis (IPF) -like lung disease. Patients and Methods: PET-Scans of 15 patients with fILD and suspected LC were acquired 10, 60 and 180 minutes after the administration of 150-250 MBq of a 68Ga labelled FAPI tracer (FAPI-46). In three patients, dynamic scans over 40 mins were performed instead of imaging after 10 minutes. Standardized uptake values (SUVmax and SUVmean) of fibrotic lesions and LC were measured and CT-density-corrected. Target-to-background ratios (TBR) were calculated. PET imaging was correlated with CT-based fibrosis scores. Time-activity curves derived from dynamic imaging were analyzed. FAP immunohistochemistry of 4 human fILD biopsy samples and of fibrotic lungs of Nedd4-2-/- mice was carried out. Results: FILD lesions as well as LC showed markedly elevated FAPI-uptake (density corrected SUVmax / mean values 60 minutes post injection: 11,12 +/- 6,71 and 4,29 +/- 1,61 for fILD lesions and 16,69 +/- 9,35 and 6,44 +/- 3,29 for LC) and high TBR (TBR of density corrected SUVmax/SUVmean values 60 minutes post injection: 2,30 +/- 1,47 and 1,67 +/- 0,79 for fILD and 3,90 +/- 2,36 and 2,37 +/- 1,14 for LC). SUVmax and SUVmean values decreased over time with stable TBR of fILD and increasing TBR in LC on trend. Dynamic imaging showed differing time activity curves of fILD and LC. FAPI uptake showed a positive correlation with the CT-based fibrosis index (FIBI). Immunohistochemistry of human biopsy samples and lungs of Nedd4-2-/- mice showed a patchy expression of FAP in fibrotic lesions, preferentially in the transition zone to healthy lung parenchyma. Conclusion: FAPI-PET/CT imaging is a promising new imaging modality for fILD and LC. Its potential clinical value for monitoring and therapy evaluation of fILD should be investigated in future studies.
000169871 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000169871 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169871 650_7 $$2Other$$aFibroblast Activation Protein
000169871 650_7 $$2Other$$aInterstitial Lung Disease
000169871 650_7 $$2Other$$aLung Cancer
000169871 650_7 $$2Other$$aPET
000169871 650_7 $$2Other$$aPET/CT
000169871 650_7 $$2Other$$aRespiratory
000169871 7001_ $$aLeitz, Dominik$$b1
000169871 7001_ $$0P:(DE-He78)1fc3c2327d9c213c36fe740ef63e1baa$$aGlatting, Frederik M$$b2
000169871 7001_ $$0P:(DE-He78)32977c5abc127b0373ece54294a41f63$$aWefers, Annika K$$b3
000169871 7001_ $$aWeinheimer, Oliver$$b4
000169871 7001_ $$aFlechsig, Paul$$b5
000169871 7001_ $$aKahn, Nicolas$$b6
000169871 7001_ $$aMall, Markus A$$b7
000169871 7001_ $$aGiesel, Frederik L$$b8
000169871 7001_ $$aKratochwil, Clemens$$b9
000169871 7001_ $$0P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aHuber, Peter E$$b10
000169871 7001_ $$0P:(DE-HGF)0$$avon Deimling, Andreas$$b11
000169871 7001_ $$aHeußel, Claus Peter$$b12
000169871 7001_ $$aKauczor, Hans Ulrich$$b13
000169871 7001_ $$aKreuter, Michael$$b14
000169871 7001_ $$0P:(DE-HGF)0$$aHaberkorn, Uwe A$$b15
000169871 773__ $$0PERI:(DE-600)2040222-3$$a10.2967/jnumed.121.261925$$gp. jnumed.121.261925 -$$n1$$p127-133$$tJournal of nuclear medicine$$v63$$x2159-662X$$y2022
000169871 909CO $$ooai:inrepo02.dkfz.de:169871$$pVDB
000169871 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1fc3c2327d9c213c36fe740ef63e1baa$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000169871 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)32977c5abc127b0373ece54294a41f63$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000169871 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000169871 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000169871 9130_ $$0G:(DE-HGF)POF3-319H$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vAddenda$$x0
000169871 9141_ $$y2021
000169871 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000169871 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-27
000169871 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000169871 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NUCL MED : 2021$$d2022-11-19
000169871 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-19
000169871 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-19
000169871 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-19
000169871 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-19
000169871 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-19
000169871 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-19
000169871 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-19
000169871 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJ NUCL MED : 2021$$d2022-11-19
000169871 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x0
000169871 980__ $$ajournal
000169871 980__ $$aVDB
000169871 980__ $$aI:(DE-He78)E055-20160331
000169871 980__ $$aUNRESTRICTED